© Reuters.
In a significant development for Eisai Co (OTC:)., the Japanese health ministry has approved its innovative Alzheimer’s disease medication, Leqembi. The decision, announced on Monday, follows a panel’s recommendation in August and comes after the drug received full endorsement from the U.S. authorities in July.
Leqembi is designed to slow down the progression of mild cognitive impairment and dementia, marking a potential breakthrough in Alzheimer’s treatment. The announcement was made by the pharmaceutical company through an official statement on Monday.
Following this news, Eisai Co.’s shares experienced a notable surge during Tokyo’s afternoon trading session. The shares rose by up to 3.5%, marking the most significant intraday increase since June. This approval has not only boosted Eisai Co.’s market performance but also signifies a crucial advancement in the global fight against Alzheimer’s disease.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Read the full article here